The Clinical Study Of Escitalopram Oxalate In The Treatment Of Chronic Subjective Dizziness

Objective:To investigate the clinical efficacy and safety of Escitalopram Oxalate in the treatment of chronic subjectivedizziness( CSD).Methods:18 cases of patients with chronic subjective dizziness,who were treated in our department between October 2014 and October 2015,were studied.The initial dose of Escitalopram Oxalate was 10mg/d, of which patients Escitalopram Oxalate- intolerant or at the age of more than 65 with the initial dose of 5mg/d, then the dose increased gradually to the best clinical benefit dose range from10 to 20mg/d. The treatment course lasted sixteen weeks. All patients were evaluated by DHI, HAMA, GAD-7, HAM-D, and PHQ-9 before and after the treatment.Repeated-measures univariate analyses of variance(ANOVA) was used to analyze the therapeutic outcome.Results: 15(80%) cases of patients finished the 16-weeks treatment, in which 12 patients were improved significantly, Six patients enjoyed a full remission of symptoms, eight of those patients had mental disorders and others without mental disorders. Our results demonstrated that the total scores of DHI, HAMA, GAD-7, HAM-D, and PHQ-9 were significantly decreased after 16-week treatment when compared with those before the treatment(P<0.05). Treatment with Escitalopram Oxalate improved symptoms of CSD, regardless of whether patients had mental disorders or not.Conclusion: Escitalopram Oxalate is an effective and safe method for CSD and can improve the symptoms of CSD involving the body, emotin and function.